GLP-1 drugs

Novo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly.

Novo Nordisk dominates the GLP-1 market with Ozempic and Wegovy, but faces stiff competition from Eli Lilly and disappointing trial results that may limit exceptional long-term returns.

Hims stock down 75% due to Novo Nordisk lawsuit over semaglutide marketing, but analysts see 150% upside potential and record revenue coming.

Novo Nordisk stock drops 15.9% after CagriSema obesity drug fails trial versus competitor tirzepatide, signaling intensifying competition in the GLP-1 market despite Wegovy's strength.

Novo Nordisk stock down 67% offers entry point for long-term investors. Strong GLP-1 market position, attractive valuation metrics, and growth potential despite upcoming competition.

Oral weight-loss drugs expand the market rather than cannibalizing injectables, attracting new patients. However, Novo Nordisk expects 2026 revenue headwinds from competition and pricing pressures.

Intuitive Surgical posts double-digit growth in 2025 with 12% installed base expansion and 18% surgery increase, unaffected by GLP-1 drug market competition.

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.

Eli Lilly acquires Orna Therapeutics for $2.4B to gain circular RNA gene therapy technology and autoimmune disease candidates, strengthening its pipeline.